Reuters logo
Vivus shareholder Aspen plans to buy company for $640 mln
May 28, 2014 / 2:20 PM / 3 years ago

Vivus shareholder Aspen plans to buy company for $640 mln

May 28 (Reuters) - Aspen Investment Fund, a shareholder of obesity drug maker Vivus Inc, said it was planning to offer to buy the company for $640 million.

Aspen, which reported a 9.65 percent stake in Vivus on Wednesday, said it expects to submit its offer to the company by June 13.

Vivus shares were up 6 percent at $4.95 in morning trading.

The company, which was embroiled in a long-drawn proxy war with another shareholder First Manhattan Co last year, has disappointed investors with weak sales of its diet pill Qsymia that was once touted as a potential blockbuster. (Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below